SS Innovations International, Inc., a developer of surgical robotic technologies, has completed a private placement generating approximately $18.6 million in gross proceeds. The financing, which occurred on March 6, 2026, involved the sale of 5,774,839 shares of common stock and was led by company directors and executive officers alongside existing and new investors.
The private placement consisted of two components. An aggregate of 1,300,006 shares were sold at an average price of $4.00 per share, raising approximately $5.2 million. This tranche included investments from Chairman and CEO Dr. Sudhir Srivastava ($2.0 million), Vice-Chairman Dr. Frederic H. Moll ($2.0 million), and director Tim Adams ($1.197 million). Additionally, 4,474,833 shares were sold at $3.00 per share, generating about $13.4 million from investors led by existing shareholder Manipal Global Health Services.
SS Innovations intends to allocate the net proceeds toward working capital and general corporate purposes, with a specific focus on advancing global expansion initiatives. According to Dr. Srivastava, the funds will support growth in India and other existing markets while preparing for entry into the United States and European Union markets. The company anticipates that the U.S. Food and Drug Administration will complete its review of the 510(k) premarket notification for the SSi Mantra surgical robotic system by mid-2026. It also continues pursuing European Union CE marking certification, which it believes can be obtained within the same year.
The insider participation in this financing reflects strong confidence in SS Innovations' future and its commitment to democratizing access to surgical robotic care. Dr. Srivastava noted appreciation for the continuing support of Manipal Global Health Services and welcomed a respected group of new shareholders. The company's product range includes the proprietary SSi Mantra surgical robotic system and the SSi Mudra surgical instruments, designed to support various procedures, including cardiac surgery. More information is available on the company's website at https://ssinnovations.com.
For business and technology leaders, this financing underscores the growing investment in medical robotics aimed at increasing accessibility. The expansion into U.S. and EU markets could intensify competition in the surgical robotics sector, potentially driving innovation and reducing costs. The clinical validation of the SSi Mantra in over 100 surgical procedures in India positions SS Innovations as a contender in a market historically dominated by higher-priced systems. The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
